FBC
AEGR

Fairfield, Bush & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

Fairfield, Bush & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-4,885
Closed -$226K – 169
2014
Q1 		$226K Buy
+4,885
New +$286K 0.11% 98
2013
Q4 		– Sell
-2,125
Closed -$182K – 275
2013
Q3 		$182K Sell
2,125
-2,706
-56% -$229K 0.06% 147
2013
Q2 		$306K Buy
+4,831
New +$256K 0.16% 108

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Fairfield, Bush & Co's AEGR Position: Q2 2014 in Review

Fairfield, Bush & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2014, closing a stake of 4,885 shares — an estimated $226K sold.

Fairfield, Bush & Co first reported a position in AEGR in Q2 2013 and held it in 3 quarters. The position peaked at $306K in Q2 2013. 129 funds tracked by Wall St. Rank hold AEGR as of Q2 2014.

  • Fairfield, Bush & Co reported no remaining Aegerion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Fairfield, Bush & Co sold 4,885 Aegerion Pharmaceuticals shares in Q2 2014, an estimated $226K.
  • Fairfield, Bush & Co first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Fairfield, Bush & Co's Aegerion Pharmaceuticals position peaked at $306K in Q2 2013.
  • 129 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2014.

Based on Fairfield, Bush & Co's 13F filing for Q2 2014, filed 15 Aug 2014.